Jonathan L. Curry, M.D., is a dermatopathologist with international expertise in cutaneous toxicities. Curry is the Medical Director of the clinical histology laboratories in the department of Pathology. He is a faculty member of the TMP-IL and serves on the CIMAC working group. Additionally, he serves on the executive committee of the Immune-Oncology Toxicity (IO-TOX) Working group at MD Anderson. Curry will be the director of the TMP-DL and will be responsible for the administration of the laboratory activities. He will provide expertise and guidance in overall program direction and will oversee the research laboratory. Curry brings clinical and translational research expertise in skin toxicities to targeted and immune checkpoint inhibitor therapy and is a recipient of departmental and institutional research grants to investigate immune mechanisms of cutaneous toxicities. Curry’s research has revealed differentially expressed genes related to recruitment of CD14+ and CD16+ monocytes and Toll-like receptors (TLRs) activation in lichenoid skin toxicities and differentially expressed genes in bullous pemphigoid toxicities. Curry’s research team is positioned to further investigate the role of the innate immune response and immune mechanisms that drive cutaneous toxicities.
Carlos Torres-Cabala, M.D., is an internationally recognized dermatopathologist and translational researcher with special expertise in acral lentiginous melanoma and cutaneous lymphoma. Torres-Cabala serves as the Section Chief in Dermatopathology and has joint appointment in the Department of Dermatology. Torres-Cabala is a member of the Executive Committee of the International Society of Dermatopathology and serves in both the Review Committee for Clinical Translational and Population-based Research projects of the Institutional Research Grants Program and the Bridge Funding Advisory Committee at MD Anderson. Torres-Cabala represents MD Anderson at the T-cell and B-cell Primary Cutaneous Lymphoma Panel of the National Comprehensive Cancer Network (NCCN). Torres-Cabala’s research has recently reported mechanisms of melanoma progression to metastasis, such as TERT amplification, and clinicopathological features of rare lymphomas, such as epidermotropic primary cutaneous T cell lymphoma. Together with Jonathan L. Curry, M.D., Torres-Cabala edited a book, Genetics of Melanoma.
Courtney W. Hudgens
Sr. Research Assistant
Courtney W. Hudgens received her Bachelor’s of Science in Biology from Austin Peay State University in Clarksville, Tennessee. After graduation, she became a histotechnician in the clinical setting before moving over to diabetes research at Vanderbilt University Medical Center. She has a background in the fields of histology, serology and molecular biology. She joined MD Anderson in 2015 as part of the Melanoma Moon Shot and has helped develop an immunohistochemistry and automated image analysis platform for the program.
Mario L. Marques-Piubelli, M.D.
Mario L. Marques-Piubelli, M.D. earned his M.D. grade at Federal University of Grande Dourados (Brazil) and did his residency training in Anatomic Pathology at University of São Paulo (Brazil). Currently, he is in the second year of his postdoctoral fellowship at MD Anderson in the Translational Molecular Pathology Department. He has special interest in skin toxicities to targeted and immune checkpoint inhibitor therapy and cutaneous lymphomas.
Debora A. Ledesma, M.D.
Debora A. Ledesma, M.D., is a postdoctoral fellow at MD Anderson in the Translational Molecular Pathology Department. She graduated from the University of Buenos Aires in Argentina. After completing her training as a dermatologist in Buenos Aires, she did a residency in Anatomic Pathology to have a better understanding of the pathology underlying skin diseases. She also did an International Fellowship in Dermatopathology for three months at Wake Forest University School of Medicine in Winston Salem, North Carolina. Debora joined the TMP department in 2018, focusing her research in melanoma and other skin cancers.